Relief Competitors

Summary

Relief Therapeutics competes with Vornado Realty, Sprinklr, Alexandria Real, Cadence Design, and Highwoods Properties; as well as few others. Analyzing Relief Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Relief Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Relief Therapeutics competition on your existing holdings.

Specify up to 10 symbols:

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Relief Therapeutics. Your research has to be compared to or analyzed against Relief Therapeutics' peers to derive any actionable benefits. When done correctly, Relief Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Relief Therapeutics.

Relief Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Relief Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Relief and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Relief Therapeutics does not affect the price movement of the other competitor.

	VNO-PL	CXM	MAHN	ARE	CDNS	HIW	JBGS	FMCKO
VNO-PL		0.09	0.0	0.48	-0.4	0.15	0.37	-0.26	VNO-PL
CXM	0.09		0.0	-0.33	0.3	0.01	0.07	0.03	CXM
MAHN	0.0	0.0		0.0	0.0	0.0	0.0	0.0	MAHN
ARE	0.48	-0.33	0.0		0.04	0.69	0.77	-0.5	ARE
CDNS	-0.4	0.3	0.0	0.04		0.41	0.29	-0.07	CDNS
HIW	0.15	0.01	0.0	0.69	0.41		0.85	-0.51	HIW
JBGS	0.37	0.07	0.0	0.77	0.29	0.85		-0.54	JBGS
FMCKO	-0.26	0.03	0.0	-0.5	-0.07	-0.51	-0.54		FMCKO
	VNO-PL	CXM	MAHN	ARE	CDNS	HIW	JBGS	FMCKO

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

JBGS	+ 0.85	HIW
JBGS	+ 0.77	ARE
HIW	+ 0.69	ARE
ARE	+ 0.48	VNO-PL
HIW	+ 0.41	CDNS
JBGS	+ 0.37	VNO-PL

High negative correlations

FMCKO	- 0.54	JBGS
FMCKO	- 0.51	HIW
FMCKO	- 0.5	ARE
CDNS	- 0.4	VNO-PL
ARE	- 0.33	CXM
FMCKO	- 0.26	VNO-PL

Risk-Adjusted Indicators

There is a big difference between Relief OTC Stock performing well and Relief Therapeutics OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Relief Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
VNO-PL	0.72	0.05	0.11	0.09	0.91	(0.78)	1.94	(1.39)	5.23
CXM	1.61	0.10	0.06	0.06	1.77	(1.89)	3.34	(2.93)	9.07
MAHN	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ARE	1.26	(0.04)	0.00	(0.15)	0.00	0.00	2.70	(2.85)	7.58
CDNS	1.74	(0.27)	0.00	(0.44)	0.00	0.00	2.72	(4.40)	13.16
HIW	1.29	(0.07)	0.00	(0.18)	0.00	0.00	2.64	(3.27)	7.07
JBGS	1.52	(0.12)	0.00	(0.36)	0.00	0.00	2.51	(3.15)	8.74
FMCKO	1.53	0.05	0.04	0.09	1.95	(2.34)	3.43	(3.64)	17.48

Unable to evaluate fundamental data of Relief Therapeutics Holding at this time. Please try again later

All Fundamental Data

Relief Therapeutics Competitive Analysis

The better you understand Relief Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Relief Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Relief Therapeutics' competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	VNO-PL	CXM	MAHN	ARE	CDNS	HIW	JBGS	FMCKO
	1.64 18.00 Vornado	2.85 8.19 Sprinklr	0.00 0.0001 Mid-Atlantic	0.31 102.17 Alexandria	3.80 233.96 Cadence	0.54 29.28 Highwoods	3.63 14.62 JBG	1.59 8.64 Federal
Market Volatility (90 Days Market Risk)	Very steady	Not too volatile	Very steady	Very steady	Very steady	Very steady	Not too volatile	Not too volatile
Market Performance (90 Days Performance)	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Above Average	Very Low	Low	Below Average	Very Low	Very Small	Below Average	Low
Current Valuation (Equity Enterprise Value)	Fairly Valued	Under Valued	Over Valued	Under Valued	Under Valued	Under Valued	Under Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Buy	Not Available	Buy	Strong Buy	Buy	Hold	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Hold	Strong Buy	Strong Sell	Strong Hold	Cautious Hold	Hold	Strong Hold	Cautious Hold
Current Ratio	1.27 X	1.99 X	1.17 X	2.90 X	1.33 X	1.46 X	4.68 X	105.75 X
Net Asset	1.19 B	1.22 B	8.89 M	37.53 B	8.97 B	6.03 B	5.02 B	3.03 T
Profit Margin	0.08 %	0.06 %	0 %	0.10 %	0.23 %	0.12 %	(0.20) %	0.50 %
EBITDA	265.75 M	49.41 M	939.29 K	1.9 B	1.67 B	474.48 M	154.58 M	N/A
Operating Margin	0.21 %	0.04 %	0.03 %	0.24 %	0.34 %	0.25 %	0.05 %	0.62 %
Current Valuation	13.54 B	1.72 B	3.91 M	29.94 B	66.47 B	6.47 B	3.72 B	2.73 T
Price To Book	N/A	4.31 X	N/A	0.99 X	14.26 X	1.36 X	0.69 X	N/A
Five Year Return	5.59 %	N/A	N/A	2.63 %	N/A	4.57 %	N/A	N/A
Retained Earnings	N/A	(474.79 M)	1.88 M	18.47 B	5.99 B	(810.61 M)	(997.28 M)	N/A
Current Asset	N/A	1.85 M	6.4 M	164.46 M	964.24 M	201.27 M	340.89 M	N/A
Beta	1.34	0.8	1.64	1.19	1.05	1.26	1.09	2.1
Number Of Employees	3.22 K	3.87 K	1.25 K	552	12.7 K	350	645	7.28 K
Shares Outstanding	N/A	138.05 M	12.06 M	173.09 M	274.11 M	107.62 M	84.48 M	3.22 B
Cash Flow From Operations	798.94 M	71.47 M	1.28 M	1.5 B	1.26 B	403.58 M	129.39 M	16.35 B
Annual Yield	0.07 %	N/A	N/A	0.05 %	N/A	0.07 %	0.05 %	N/A
Total Debt	8.04 B	33.29 M	401.76 K	12.75 B	2.48 B	3.29 B	2.62 B	2.98 T
Return On Equity	0.0237	0.0763	0.0123	0.0227	0.26	0.0424	-0.0557	0.34
Z Score	1.6	N/A	3.0	N/A	N/A	N/A	N/A	N/A
Return On Asset	0.0142	0.0186	0.0608	0.0142	0.12	0.0225	0.002	0.0034
Number Of Shares Shorted	20.04 K	9.36 M	N/A	3.36 M	4.29 M	4.44 M	7.22 M	2.54 K
Book Value Per Share	27.40 X	1.95 X	0.18 X	103.88 X	17.07 X	21.67 X	22.29 X	(16.00) X
Current Liabilities	N/A	1.17 M	5.46 M	651.36 M	536.31 M	248.11 M	174.69 M	N/A
Total Asset	1.19 B	1.22 B	8.89 M	37.53 B	8.97 B	6.03 B	5.02 B	3.03 T
Debt To Equity	154.40 %	0.03 %	2.06 %	0.51 %	0.29 %	1.15 %	0.60 %	N/A
Short Ratio	1.03 X	6.94 X	N/A	2.52 X	2.78 X	4.66 X	14.68 X	0.02 X
Last Dividend Paid	2.12	N/A	N/A	5.19	N/A	2.0	0.7	N/A
Target Price	N/A	10.21	N/A	118.25	323.93	31.38	15.5	N/A
Shares Owned By Institutions	24.60 %	93.47 %	N/A	98.45 %	91.97 %	98.01 %	96.22 %	N/A
Market Capitalization	10.06 B	2.14 B	2.41 K	17.74 B	66.67 B	3.23 B	1.28 B	1.5 B
Price To Earning	8.43 X	N/A	7.00 X	46.42 X	58.71 X	11.88 X	297.26 X	11.33 X
Price To Earnings To Growth	N/A	0.72 X	N/A	844.20 X	2.56 X	5.09 X	4.80 X	N/A
Price To Sales	4.84 X	2.72 X	0.01 X	5.68 X	14.36 X	3.89 X	2.29 X	0.07 X
Net Income	(382.61 M)	51.4 M	(35.2 K)	510.73 M	1.06 B	104.25 M	(177.75 M)	12.11 B
Earnings Per Share	0.64 X	0.15 X	0 X	1.80 X	3.84 X	0.94 X	(1.28) X	0.07 X
Shares Owned By Insiders	N/A	6.78 %	N/A	1.20 %	1.01 %	1.99 %	0.04 %	N/A
Revenue	1.8 B	732.36 M	28.34 M	3.12 B	4.64 B	830.02 M	547.31 M	4.37 B
Working Capital	N/A	492.82 M	937 K	(1.17 B)	2.65 B	207.76 M	183.05 M	N/A
Cash And Equivalents	326.66 M	188.39 M	750.28 K	825.19 M	1.03 B	21.36 M	162.27 M	91.52 B
Cash Per Share	1.71 X	2.08 X	0.06 X	3.25 X	3.74 X	0.22 X	1.42 X	28.41 X
Gross Profit	907.84 M	577.55 M	6.31 M	2.21 B	3.99 B	557.85 M	289.01 M	22.99 B
Day Typical Price	18.09	8.24	1.0E-4	103.0	234.76	29.4	14.89	8.58
Accumulation Distribution	295.95	48633.35	N/A	46332.38	92125.35	62621.25	70213.76	0.022
Market Facilitation Index	0.0	N/A	N/A	0.0	0.0	N/A	0.0	0.19
Daily Balance Of Power	(1.11)	(1.00)	0.0	(0.09)	(1.27)	(0.17)	(0.60)	(0.74)
Period Momentum Indicator	(0.30)	(0.24)	N/A	(0.32)	(9.25)	(0.16)	(0.55)	(0.14)
Rate Of Daily Change	0.98	0.97	1.0	1.0	0.96	0.99	0.96	0.98
Day Median Price	18.13	8.27	1.0E-4	103.42	235.16	29.47	15.03	8.55
Price Action Indicator	(0.29)	(0.20)	N/A	(1.40)	(5.83)	(0.26)	(0.69)	0.025
Coefficient Of Variation	2502.68	3684.0	N/A	(2,173)	(771.43)	(1,561)	(1,364)	6595.06
Mean Deviation	0.7216	1.61	N/A	1.26	1.74	1.29	1.52	1.53
Jensen Alpha	0.0549	0.1018	N/A	(0.04)	(0.27)	(0.07)	(0.12)	0.0547
Total Risk Alpha	0.1259	0.2333	N/A	0.0715	(0.09)	0.0424	0.033	0.2742
Sortino Ratio	0.11	0.0641	N/A	N/A	N/A	N/A	N/A	0.0415
Downside Variance	0.9208	3.46	N/A	N/A	N/A	N/A	N/A	6.34
Standard Deviation	1.0	1.99	N/A	1.65	2.47	1.68	1.96	2.57
Kurtosis	1.61	(0.45)	N/A	0.5404	3.83	0.5333	1.16	6.21
Potential Upside	1.94	3.34	N/A	2.7	2.72	2.64	2.51	3.43
Treynor Ratio	0.0916	0.0573	N/A	(0.15)	(0.44)	(0.18)	(0.36)	0.0854
Maximum Drawdown	5.23	9.07	N/A	7.58	13.16	7.07	8.74	17.48
Variance	1.01	3.95	N/A	2.74	6.11	2.82	3.83	6.62
Market Risk Adjusted Performance	0.1016	0.0673	N/A	(0.14)	(0.43)	(0.17)	(0.35)	0.0954
Risk Adjusted Performance	0.0337	0.0275	N/A	(0.03)	(0.1)	(0.05)	(0.05)	0.0189
Skewness	0.3433	0.1784	N/A	(0.27)	(1.56)	(0.44)	(0.58)	1.28
Semi Deviation	0.9075	1.77	N/A	N/A	N/A	N/A	N/A	1.95
Information Ratio	0.1051	0.0601	N/A	(0.01)	(0.10)	(0.03)	(0.04)	0.0406
Value At Risk	(1.39)	(2.93)	N/A	(2.85)	(4.40)	(3.27)	(3.15)	(3.64)
Expected Short fall	(0.78)	(1.89)	N/A	N/A	N/A	N/A	N/A	(2.34)
Downside Deviation	0.9596	1.86	N/A	N/A	N/A	N/A	N/A	2.52
Semi Variance	0.8236	3.12	N/A	N/A	N/A	N/A	N/A	3.79

Relief Therapeutics Competition Performance Charts

Five steps to successful analysis of Relief Therapeutics Competition

Relief Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Relief Therapeutics in relation to its competition. Relief Therapeutics' competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Relief Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Relief Therapeutics' competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Relief Therapeutics, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Relief Therapeutics position

In addition to having Relief Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities Thematic Idea Now

Utilities

Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.

View All Next

Launch

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census.

Note that the Relief Therapeutics information on this page should be used as a complementary analysis to other Relief Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Consideration for investing in Relief OTC Stock

If you are still planning to invest in Relief Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Relief Therapeutics' history and understand the potential risks before investing.

	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC